![]() Her wide range of interests varies from AI in health care to D&I initiatives that have been embodied through her contributions to print and media as well as at conferences across the globe. To further her passion for teaching, she served as an Honorary Lecturer in Medical Education and Simulation at the University of Adelaide Medical School, Australia. Badhrinarayanan received the Edward Jenner Award from the NHS Leadership Academy. Thriving in the field of medical leadership and management, Dr. Prior to her current position, she served as a Physician with the National Health Service (NHS) in the UK, where she made significant contributions to clinical and research initiatives. In this role, she provides strategic direction for the development of new Immuno-Oncology drugs by leading cross-functional teams and conducting medical monitoring of clinical trials. Shreya Badhrinarayanan is the Medical Director for Clinical Development Oncology at Genentech, a subsidiary of Roche. Off the professional grid, Michigan is where he calls home, enjoying moments with his family and passionately supporting blood drives as a regular donor.ĭr. Beyond Takeda, Pat amassed experience across functions in companies such as Millennium Pharmaceuticals and Johnson & Johnson.Įducationally, Pat boasts an MBA with a concentration in Healthcare Leadership from Oakland University and a BS from Hillsdale College. During these years, Pat was actively involved in nine oncology product launches and contributed to several post-acquisition integrations, demonstrating adaptability and commitment. His experience at Takeda also includes a notable tenure as a National Sales Leader. As a part of the US Oncology Leadership Team, he had purview over areas like Launch Excellence, Marketing Operations, Digital Operations, and Learning and Development. At Takeda Oncology, he served as the Head of US Strategy and Operations. His journey prior to NCODA spanned a diverse 25 years in the pharmaceutical and biotech arenas. In his role, Pat oversees multiple core divisions, such as Business Development, Marketing, Communications, Public Relations, Member Events, and Partner Agreements. With a deep-seated belief in the potential of the pharmaceutical sector, Pat consistently endeavors to cultivate enriching collaborations between NCODA members and pharmaceutical partners, aiming to elevate patient outcomes via enhanced education. Patrick (Pat) Connelly serves as the Chief Development and Strategy Officer at NCODA, a pivotal role that sees him shaping the organization’s growth strategy and long-term objectives. For more information about NCODA visit or follow on LinkedIn. NCODA is a leading non-profit association dedicated to empowering medically integrated oncology practices to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards, and best practices. ![]() If you have any further questions regarding policy news and/or NCODA legislative initiatives, email Kevin Scorsone (NCODA’s Legislative & Policy Liaison) at NCODA The tracker includes the full bill to read, and also includes a summary and “why it matters” section to educate our membership in a thorough and timely manner. This state-of-the-art and first-of-its-kind tracker is updated weekly and features oncology related bills from all 50 states. Important updates such as this can be found in the newly released NCODA Oncology State Legislation Tracker. ![]() ![]() We believe that it is time for continued copay accumulator and PBM reform. NCODA firmly believes that states have taken notice of the reform currently taking place around the country. These requirements do not apply for drugs with generic alternatives, unless the covered individual obtained the brand-name drug through a prior authorization, step therapy override exemption, or other exemption or appeal process.īy including any waivers or discounts provided by third parties on behalf of a covered individual and counting them towards the individual’s cost-sharing responsibility under his/her health plan, the covered individual will be able to get their prescription faster and easier. Starting on or after January 1st, 2023, this law makes sure that an individual’s health plan or pharmacy benefit manager does not exclude any waivers or discounts provided by third parties on behalf of the covered individual when the health plan calculates the individual’s contribution to any cost-sharing requirement of their health plan (including the deductible, copayment, and out-of-pocket maximum). We are thrilled that the state of Maine has passed sweeping copay accumulator reform that has resulted in SB 1783 being passed and enacted on April 25. STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEEĬontact: Kevin Scorsone | NCODA Legislative & Policy LiaisonĬopay accumulator reform has been sweeping the nation so far this year.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |